BACKGROUND: We investigated the clinical implications of global hypomethylation, one of the most consistent epigenetic changes in cancer, in the sera of patients with hepatocellular carcinoma (HCC). METHODS: Combined bisulfite restriction analysis PCR was used to assess the methylation status of LINE-1 repetitive sequences in genomic DNA derived from sera of 85 patients with HCC, 73 patients with cirrhosis, 20 healthy carriers of hepatitis B virus (HBV) and 30 healthy controls. RESULTS: Serum genome hypomethylation, the percentage of unmethylated LINE-1, was significantly increased in patients with HCC (P<0.001). The levels of serum LINE-1 hypomethylation at initial presentation correlated significantly with the presence of HBsAg, large tumor sizes, and advanced tumor stages classified by the CLIP score. Multivariate analyses showed that serum LINE-1 hypomethylation was a significant and independent prognostic factor of overall survival. CONCLUSION: Serum LINE-1 hypomethylation may serve as a prognostic marker for patients with HCC.
BACKGROUND: We investigated the clinical implications of global hypomethylation, one of the most consistent epigenetic changes in cancer, in the sera of patients with hepatocellular carcinoma (HCC). METHODS: Combined bisulfite restriction analysis PCR was used to assess the methylation status of LINE-1 repetitive sequences in genomic DNA derived from sera of 85 patients with HCC, 73 patients with cirrhosis, 20 healthy carriers of hepatitis B virus (HBV) and 30 healthy controls. RESULTS: Serum genome hypomethylation, the percentage of unmethylated LINE-1, was significantly increased in patients with HCC (P<0.001). The levels of serum LINE-1 hypomethylation at initial presentation correlated significantly with the presence of HBsAg, large tumor sizes, and advanced tumor stages classified by the CLIP score. Multivariate analyses showed that serum LINE-1 hypomethylation was a significant and independent prognostic factor of overall survival. CONCLUSION: Serum LINE-1 hypomethylation may serve as a prognostic marker for patients with HCC.
Authors: Zhong-Zheng Zhu; David Sparrow; Lifang Hou; Letizia Tarantini; Valentina Bollati; Augusto A Litonjua; Antonella Zanobetti; Pantel Vokonas; Robert O Wright; Andrea Baccarelli; Joel Schwartz Journal: Cancer Causes Control Date: 2010-12-25 Impact factor: 2.506
Authors: Eric J Formeister; Masato Tsuchiya; Hideki Fujii; Svitlana Shpyleva; Igor P Pogribny; Ivan Rusyn Journal: Mutat Res Date: 2010-08-22 Impact factor: 2.433
Authors: Chih-Ching Yeh; Abhishek Goyal; Jing Shen; Hui-Chen Wu; Joshua A Strauss; Qiao Wang; Irina Gurvich; Rachael A Safyan; Gulam A Manji; Mary V Gamble; Abby B Siegel; Regina M Santella Journal: Ann Surg Oncol Date: 2017-06-07 Impact factor: 5.344
Authors: K C Allen Chan; Peiyong Jiang; Carol W M Chan; Kun Sun; John Wong; Edwin P Hui; Stephen L Chan; Wing Cheong Chan; David S C Hui; Simon S M Ng; Henry L Y Chan; Cesar S C Wong; Brigette B Y Ma; Anthony T C Chan; Paul B S Lai; Hao Sun; Rossa W K Chiu; Y M Dennis Lo Journal: Proc Natl Acad Sci U S A Date: 2013-11-04 Impact factor: 11.205